P38α MAPK Signaling—A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease

by Ursula A. Germann, John J. Alam
Published 2020-07-01

Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied b...

by John J Alam, Michael Krakovsky, Ursula Germann, Aharon Levy
Published 2020-01-01

A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.

by Bambang S Adiwijaya, Tara L Kieffer, Joshua Henshaw, Karen Eisenhauer, Holly Kimko, John J Alam, Robert S Kauffman, Varun Garg
Published 2012-01-01

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

by Niels D. Prins, John E. Harrison, Hui-May Chu, Kelly Blackburn, John J. Alam, Philip Scheltens, for the REVERSE-SD Study Investigators
Published 2021-05-01